Speech-Language Pathologists in Milton, WA Accepting Medicare
3 Speech-Language Pathologists found. Showing 1 - 3
 Lindsay Jennifer Wilkison, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 74 20th Ave Crt, Milton, WA 98354 Phone: 360-389-8307 |
Mrs. Jennifer S. Gonzalez, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1205 19th Ave, Milton, WA 98354 Phone: 253-517-1200 |
Ms. Amy Battle Mcmillan, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1205 19th Ave, Milton, WA 98354 Phone: 253-517-1000 |
News Archive
Positive results from Phase 1 study evaluating IV administration of JX-594 to metastatic cancer patients
Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous administration of JX-594 to patients with metastatic cancer. The data presented today demonstrated clear dose-related delivery to solid tumors, cancer-targeted replication and gene expression, and anti-cancer effects of JX-594 delivered IV.
Waist size can predict diabetes risk
A higher rate of diabetes seen among adult Americans when compared to peers in England is explained primarily by a larger waist size rather than conventional risk factors such as obesity, according to a new study by researchers from the RAND Corporation, University College London and the Institute for Fiscal Studies in London.
Researchers to study whether menstrual cups can help prevent vaginal infections
Researchers at the University of Illinois at Chicago will conduct a study to determine how the use of menstrual cups helps prevent vaginal infections and sexually transmitted infections.
One single genomic fingerprinting could potentially miss smaller, more aggressive prostate tumors
While the majority of prostate cancers are slow growing and not fatal, some are aggressive and lethal.
Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015
Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma.
› Verified 2 days ago
Optometrists
Chiropractors
Speech-Language Pathologists
Physical Therapists
Podiatrists
Occupational Therapists